|Haynes: B cell Lineage Envelope Design from RV144 Antibodies
|Prophylactic neutralizing Ab
|Study Start Date:
|Study Made Public:
Neutralization activity of antibodies Ab53042.1 and Ab530402.2, from an RV305 participant, tested against an expanded tier 2 virus panel
CAVD 524 is an immunogenicity study to characterize the neutralization of monoclonal antibodies from a single subject in the RV305 vaccine clinical trial.
Sign in to see full information about this study and to download study data.